Zhejiang Medicine Co (SHSE:600216) Ending Cash Position: ¥3,365 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600216 Zhejiang Medicine Co Ltd SHSE:600216
76 GF Score
Price ¥12.93
GF Value ¥13.89
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Zhejiang Medicine Co Ending Cash Position?

Zhejiang Medicine Co SHSE:600216 -1.97% 76 Ending Cash Position is ¥3,365 Mil as of Jun. 2026. GuruFocus rates SHSE:600216 with a GF Score™ of 76/100 and a GF Value™ of ¥13.89 (Fairly Valued). The stock has 6 warning signs investors should review.

Zhejiang Medicine Co's Ending Cash Position for the quarter that ended in Jun. 2026 was ¥3,365 Mil.

Zhejiang Medicine Co's quarterly Ending Cash Position declined from Dec. 2025 (¥3,167 Mil) to Mar. 2026 (¥2,977 Mil) but then increased from Mar. 2026 (¥2,977 Mil) to Jun. 2026 (¥3,365 Mil).

Zhejiang Medicine Co's annual Ending Cash Position increased from Dec. 2023 (¥1,460 Mil) to Dec. 2024 (¥1,966 Mil) and increased from Dec. 2024 (¥1,966 Mil) to Dec. 2025 (¥3,167 Mil).

Zhejiang Medicine Co Ending Cash Position Related Terms

Zhejiang Medicine Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Zhejiang Medicine Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Medicine Co Ending Cash Position Chart

Zhejiang Medicine Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,768.53 1,437.91 1,459.84 1,965.59 3,166.83

Zhejiang Medicine Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,708.61 2,899.00 3,166.83 2,976.85 3,364.64
SHSE:600216
76GF Score
Zhejiang Medicine Co Ltd SHSE:600216
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Medicine Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Zhejiang Medicine Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1965.586+1201.246
=3,167

Zhejiang Medicine Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2976.852+387.79
=3,365

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ¥3,365 Mil mean?
Zhejiang Medicine Co (SHSE:600216) has a Ending Cash Position of ¥3,365 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Zhejiang Medicine Co and its competitors.
Is Zhejiang Medicine Co's Ending Cash Position too high?
Zhejiang Medicine Co's current Ending Cash Position is ¥3,365 Mil. Overall, Zhejiang Medicine Co has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Medicine Co's Ending Cash Position compare to ZTS?
Zhejiang Medicine Co's Ending Cash Position of ¥3,365 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Zhejiang Medicine Co and its competitors. Zhejiang Medicine Co's current Ending Cash Position is ¥3,365 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Medicine Co (SHSE:600216) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.89, compared to a current price of ¥12.93 — trading 6.9% below its estimated fair value. The current Ending Cash Position is ¥3,365 Mil. Zhejiang Medicine Co's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Zhejiang Medicine Co (SHSE:600216), the current Ending Cash Position is ¥3,365 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Medicine Co (SHSE:600216) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Medicine Co stock appears to be undervalued. The current stock price of ¥12.93 is trading 6.9% below its estimated GF Value™ of ¥13.89. GuruFocus considers Zhejiang Medicine Co to be Fairly Valued.

Key valuation signals for SHSE:600216:

  • Ending Cash Position: ¥3,365 Mil
  • GF Value™: ¥13.89 vs. price of ¥12.93 (6.9% below fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Medicine Co Business Description

Address Comprehensive Building, No. 398 Mahuan Road, 3rd Floor, Building A, Binhai New City, Shaoxing, CHN, 312366
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
76GF Score

Get the complete analysis for SHSE:600216

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.93
Price
¥13.89
GF Value